Dramatic improvement of pyoderma gangrenosum with infliximab in a patient with PAPA syndrome.

Abstract

Infliximab, a chimeric antitumor necrosis factor alpha monoclonal antibody (anti-TNF alpha), has been recently shown to have a beneficial effect on pyoderma gangrenosum associated with inflammatory bowel disease. Patients with the syndromic triad of pyogenic sterile arthritis, pyoderma gangrenosum, and acne, an autoinflammatory process caused by mutations in the CD2 binding protein-1 (CD2BP1) gene, can have severe pyoderma gangrenosum. We describe a 14-year-old patient with this syndrome who was unresponsive to multiple therapies. A dramatic improvement in his pyoderma gangrenosum was observed after one infusion of infliximab, and a second infusion led to its resolution. Our observation extends the therapeutic use of infliximab to this component of PAPA syndrome.

• Authors: Dorothee S Stichweh, Marilynn Punaro, Virginia Pascual
• Journal: Pediatric dermatology (Pediatr Dermatol) 2005 May-Jun Vol. 22 Issue 3 Pg. 262-5 ISSN: 0736-8046 [Print] United States
• PMID: 15916580 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antibodies, Monoclonal
• Dermatologic Agents
• Infliximab

Topics

• Acne Vulgaris (genetics)
• Adolescent
• Antibodies, Monoclonal (therapeutic use)
• Arthritis (genetics)
• Dermatologic Agents (therapeutic use)
• Humans
• Infliximab
• Male
• Pyoderma Gangrenosum (drug therapy, genetics)
• Syndrome